Why is Peter N. Kellogg leaving his position as CFO?

The filing states that Mr. Kellogg and Merck mutually agreed that his term as CFO would end after seven years of service. He will remain with the company until May 16, 2014, to support a smooth transition.

Who is replacing Peter N. Kellogg as CFO?

Robert M. Davis has been appointed as the new Executive Vice President and Chief Financial Officer, effective April 23, 2014. He previously held senior roles at Baxter International, Inc., including CFO.

What is the compensation package for the new CFO, Robert M. Davis?

Mr. Davis will receive an annual base salary of $950,000, be eligible for a target bonus of 95% of his base salary, and receive a long-term incentive grant with a target value of $3,500,000. He is also receiving a $5 million sign-on bonus and an RSU grant valued at approximately $5 million.

Are there any special conditions attached to Robert M. Davis's sign-on bonus?

Yes, the $5 million sign-on bonus is payable in installments over two years and is contingent upon his continued employment for 24 months following his start date. However, if his employment is terminated by the company for reasons other than 'Cause' (as defined), or due to his death or disability, he is entitled to retain portions already paid or receive future installments as per the agreement.

MRK 8-K: Leadership Changes

Summary

This 8-K filing from Merck & Co., Inc. announces a significant leadership change in its finance department. Peter N. Kellogg, Executive Vice President and Chief Financial Officer, will be departing the company effective April 23, 2014, after seven years of service. He will remain with Merck until May 16, 2014, to ensure a smooth transition and will receive severance benefits in accordance with his existing offer letter, contingent upon signing a release agreement. Concurrently, Merck has appointed Robert M. Davis as the new Executive Vice President and Chief Financial Officer, also effective April 23, 2014. Mr. Davis brings extensive experience from Baxter International, Inc., where he most recently served as Corporate Vice President and President of Medical Products and previously as their CFO. His compensation package includes a base salary of $950,000, a target bonus of 95%, a significant long-term incentive grant, a substantial sign-on bonus of $5 million, and an RSU grant valued at approximately $5 million, with portions of these awards intended to compensate for forfeited equity at his prior employer.

Key Highlights

1Peter N. Kellogg is stepping down as CFO after seven years of service, with his tenure ending April 23, 2014.
2Robert M. Davis has been appointed as the new Executive Vice President and Chief Financial Officer, effective April 23, 2014.
3Mr. Davis joins Merck from Baxter International, Inc., bringing significant financial and operational leadership experience.
4Mr. Davis's compensation package includes a $950,000 base salary and a target bonus of 95% of base salary for 2014.
5A substantial sign-on bonus of $5 million, payable over two years, is part of Mr. Davis's compensation, with a significant portion intended to offset forfeited equity from Baxter.
6Mr. Davis will also receive an RSU grant valued at approximately $5 million, vesting over three years.
7Severance terms for Mr. Kellogg have been extended, providing a lump sum payment equal to 18 months of base salary, subject to a release agreement.

Merck & Co., Inc. 8-K Report, Executive Changes (Mar 27, 2014)

Summary

Key Highlights

Frequently Asked Questions